To evaluate the effect of preoperative statin treatment on the outcome of primary vitrectomy in type 1 and 2 diabetic patients.
Methods
In this open, observational institutional study, a total of 192 eyes of 171 type 1 and 2 adult diabetic patients admitted for primary vitrectomy for management of sight-threatening forms of diabetic retinopathy were divided according to the use of lipid-lowering therapy: those with statin treatment (79 eyes of 73 patients) and those taking no statin medication (113 eyes of 98 patients). One-month best-corrected visual acuity (BCVA) gain and cumulative 12-month revitrectomy frequency were analyzed.
Results
In multivariate linear regression, diabetic patients with statin treatment had a better 1-month BCVA improvement than did those without statin treatment (absolute difference 0.26, 95% confidence interval [CI] 0.02-0.50, p = 0.028). Subgroup analysis revealed that diabetic patients on statin had better postoperative BCVA improvement when preoperative status included partial or panretinal laser photocoagulation (p = 0.042 and p = 0.049) and anti-vascular endothelial growth factor therapy (p = 0.011). Moreover, diabetic patients with preoperative macular edema (p = 0.009), vitreous hemorrhage (p<0.001), proliferative retinopathy (p<0.001), or tractional retinal detachment (p = 0.010) had better BCVA recovery if receiving statin. In Cox proportional hazards regression model, revitrectomies in our 12-month follow-up were less frequent in diabetic patients on statin treatment (hazard ratio 0.28, 95% CI 0.08-0.93, p = 0.037).
Conclusions
These data provide novel insight into the potential clinical benefit for patients with sight-threatening diabetic retinopathy undergoing vitrectomy treated with statin.
Get full access to this article
View all access options for this article.
References
1.
KempenJHO'ColmainBJLeskeMC; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol2004;122:552–63
2.
ZhangXSaaddineJBChouCFPrevalence of diabetic retinopathy in the United States, 2005-2008. JAMA2010;304:649–56
3.
BlankenshipGWMachemerRLong-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology1985;92:503–6
4.
OstriCLuxALund-AndersenHla CourMLong-term results, prognostic factors and cataract surgery after diabetic vitrectomy: a 10-year follow-up study. Acta Ophthalmol2014;92:571–6
5.
JoussenAMJoeresSBenefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev Ophthalmol2007;39:69–87
6.
AvitabileTBonfiglioVCastiglioneFCastaingMContarinoFMistrettaASevere proliferative diabetic retinopathy treated with vitrectomy or panretinal photocoagulation: a monocenter randomized controlled clinical trial. Can J Ophthalmol2011;46:345–51
7.
GuptaBWongRSivaprasadSWilliamsonTHSurgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice. Eye2012;26:576–82
8.
KohKKEffects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res2000;47:648–57
9.
BonettiPOWilsonSHRodriguez-PorcelMHolmesDRJrLermanLOLermanASimvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol2002;40:546–54
10.
WilsonSHSimariRDBestPJSimvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol2001;21:122–8
11.
UndasABrummelKEMusialJMannKGSzczeklikASimvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation2001;103:2248–53
12.
AliFHamdulaySSKinderlererARStatin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost2007;5:2537–46
13.
SanguigniVPignatelliPLentiLShort-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation2005;111:412–9
14.
Hernández-PereraOPérez-SalaDNavarro-AntolínJEffects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest1998;101:2711–9
15.
UndasACelińska-LowenhoffMStepieńENizankowskiRTraczWSzczeklikAEffects of simvastatin on angiogenic growth factors released at the site of microvascular injury. Thromb Haemost2006;95:1045–7
16.
LeeSGKimJLLeeHKSimvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes. Graefes Arch Clin Exp Ophthalmol2011;249:389–97
17.
PasceriVPattiGNuscaAPristipinoCRichichiGDi SciascioGARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation2004;110:674–8
18.
Le ManachYIbanez EstevesCBertrandMImpact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing vascular surgery. Anesthesiology2011;114:98–104
19.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7–22
20.
CollinsRArmitageJParishSSleighPPetoRHeart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361:2005–16
21.
ShepherdJBarterPCarmenaREffect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care2006;29:1220–6
22.
SenKMisraAKumarAPandeyRMSimvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract2002;56:1–11
23.
ChewEYAmbrosiusWTDavisMD; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med2010;363:233–44
24.
MiyaharaSKiryuJYamashiroKSimvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol2004;164:1697–706
25.
TuuminenRSahanneSLoukovaaraSLow intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment. Acta Ophthalmol2014;92:675–81
26.
LoukovaaraSRobciucAHolopainenJMAng-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol2013;91:531–9
27.
Schulze-BonselKFeltgenNBurauHHansenLBachMVisual acuities “hand motion” and “counting fingers” can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci2006;47:1236–40
28.
AielloLPAveryRLArriggPGVascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med1994;331:1480–7
29.
SchachterMChemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fund Clin Pharmacol2005;19:117–25
30.
MasonRPWalterMFDayCAJacobRFIntermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol2005;96:11F–23F
31.
HilbertTPothJFredeSAnti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells. Biochem Pharmacol2013;86:1452–60
32.
KawaharaSHataYKitaTPotent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. Diabetes2008;57:2784–93
33.
ZhangWYanHSimvastatin increases circulating endothelial progenitor cells and reduces the formation and progression of diabetic retinopathy in rats. Exp Eye Res2012;105:1–8
34.
KeechACMitchellPSummanenPA; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet2007;370:1687–97
35.
ChewEYAmbrosiusWTDavisMD; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med2010;363:233–44
36.
StefánssonEThe therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand2001;79:435–40
37.
ZaccoATogoJSpenceK3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci2003;23:11104–11
38.
LimJHLeeJCLeeYHSimvastatin prevents oxygen and glucose deprivation/reoxygenation-induced death of cortical neurons by reducing the production and toxicity of 4-hydroxy-2E-nonenal. J Neurochem2006;97:140–50
39.
KoMLChenCFPengPHPengYHSimvastatin upregulates Bcl-2 expression and protects retinal neurons from early ischemia/reperfusion injury in the rat retina. Exp Eye Res2011;93:580–5
40.
NagaokaTTakahashiASatoEEffect of systemic administration of simvastatin on retinal circulation. Arch Ophthalmol2006;124:665–70
41.
ScheitzJFSeiffgeDJTütüncüSDose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke. Stroke2014;45:509–14
42.
LeungDYLiFCKwongYYThamCCChiSCLamDSSimvastatin and disease stabilization in normal tension glaucoma: a cohort study. Ophthalmology2010;117:471–6
43.
LeiterLALundmanPda SilvaPMDrexelHJüngerCGittAKDYSIS investigators. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med2011;28:1343–51
44.
SierraSRamosMCMolinaPEsteoCVázquezJABurgosJSStatins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis2011;23:307–18
45.
TuuminenRSyrjäläSKrebsRDonor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection. Circulation2011;124:1138–50
46.
HartleyKLSmiddyWEFlynnHWJrMurrayTGPars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina2008;28:410–9
47.
PyŏräläKPedersenTRKjekshusJFaergemanOOlssonAGThorgeirssonGCholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997;20:614–20
48.
RuokoniemiPSundRArffmanMAre statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. BMJ Open2014;4:e005402
49.
TuomilehtoJThe emerging global epidemic of type 1 diabetes. Curr Diab Rep2013;13:795–804
50.
NakazawaMKimizukaYWatabeTVisual outcome after vitrectomy for diabetic retinopathy. A five-year follow-up. Acta Ophthalmol1993;71:219–23
